Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry

Key facts

Sponsor

University of Rochester

Principal Investigator

Johann Hamel, MD

University of Rochester Medical Center, Department of Neurology

Enrollment

3000 enrolled

Eligibility

All sexes

Timeline

2000 – 2028

Study locations (1)

• University of Rochester Medical Center, Department of Neurology, Rochester, New York, United States

Collaborators

National Institute of Neurological Disorders and Stroke (NINDS)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Proximal myotonic myopathy

Additional recruiting or active studies for the same condition.

• ENROLLING BY INVITATIONPHASE3NCT06549400
  An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 Who Have Completed MEX-DM-302 Study.
  Lupin Ltd.
• RECRUITINGPHASE1, PHASE2NCT06844214
  A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 50 Years of Age With Non-congenital Myotonic Dystrophy Type 1
  Sanofi
• RECRUITINGNANCT06716931
  Investigating Exercise in Myotonic Dystrophy Type 2 (DM2)
  Massachusetts General Hospital
• RECRUITINGPHASE3NCT06523400
  The Efficacy and Safety of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2
  Lupin Ltd.
• RECRUITINGNCT05854433
  Brain Structure and Clinical Endpoints in Myotonic Dystrophy Type 2
  Wake Forest University Health Sciences
• RECRUITINGNCT04003363
  The United Kingdom National Registry for Myotonic Dystrophy
  Newcastle University
• RECRUITINGNCT02398786
  Myotonic Dystrophy Family Registry
  Myotonic Dystrophy Foundation

See all trials for Proximal myotonic myopathy →